CORRONA Registry shows no difference in 1 year outcomes when RA patients are given 1st line TNF inhibitors compared to 1st line non-TNF biologics (ABA, TCZ, RTX, anakinra, TOFA: thus supporting current RA guidelines, recommending individualised care https://t.co/YWJicBMAAK